Objectives: Adrenergic receptor (ADR) genotypes have been associated with adverse outcomes in heart failure. Our objective was to evaluate the association of ADR genotypes with post-Norwood outcomes in infants with hypoplastic left heart syndrome (HLHS).
Single-ventricle lesions comprise more than 7% of all congenital heart defects, with hypoplastic left heart syndrome (HLHS) being the most common lesion. 1, 2 In HLHS, a single right ventricle (RV) acts as a systemic ventricle, whereas the left ventricle is hypoplastic or rudimentary. Patients with HLHS require multiple palliative surgeries to separate the pulmonary and systemic circulations with the first staged palliation, ie, the Norwood procedure, performed in the newborn period. Maintenance of systemic cardiac output after the Norwood procedure requires a balance between the systemic and pulmonary circulations and adequate RV function. Abnormal systemic and pulmonary vascular resistance and ventricular dysfunction are major contributors to maladaptation to a single-ventricle physiology. In one analysis, up to 40% of patients with staged palliation were noted to have some degree of heart failure. 3 Single-ventricle patients have fragile hemodynamics and are especially vulnerable after cardiac surgery. The postoperative physiological stress response involves a surge in endogenous catecholamine production, which can have profound effects on cardiac function and vascular tone mediated by adrenergic receptors. Adrenergic receptors include presynaptic a2a and a2c receptors that inhibit norepinephrine release, cardiac b1 receptors that mediate chronotropic and inotropic response to norepinephrine, and b2 receptors that mediate vascular smooth muscle relaxation and response to b-blockers. 4 Adrenergic upregulation is an important mechanism of cardiovascular adaptation during stress, particularly in the infant, in whom the circulation is highly catecholamine-dependent. 5, 6 Although acute upregulation is compensatory, chronic upregulation can have detrimental effects by increasing systemic and pulmonary vascular resistance and increasing myocardial oxygen demands, resulting in adverse cardiac remodeling and ventricular dysfunction. 4, [7] [8] [9] [10] [11] [12] In children with dilated cardiomyopathy, a2 and b1 upregulation and b2 downregulation genotypes were associated with worse ventricular function, progression of heart failure, and acute hemodynamic decompensation. 13 The impact of adrenergic receptor genotypes on adaptation to hemodynamic and surgical stress in infants with HLHS undergoing staged palliation is not known. We hypothesized that genetic modulation of receptor activity would alter catecholamine response and thereby influence postoperative clinical course. The purpose of our study was to evaluate whether genetic variants that upregulate adrenergic receptor activity adversely impact post-Norwood outcomes in infants with HLHS enrolled in the Single Ventricle Reconstruction Trial (SVR Trial).
METHODS

Study Population
This is an ancillary study that derives from the Pediatric Heart Network (PHN) SVR Trial, in which infants with HLHS (n ¼ 555) were enrolled from 15 North American centers between May 2005 and July 2008. The details of the study design, inclusion criteria, study assessments, as well as trial results have been published previously. 14, 15 In brief, inclusion criteria for the SVR Trial included a diagnosis of HLHS or a related single morphologic RV anomaly, planned Norwood procedure, and absence of a genetic or medical condition that would affect transplantfree survival. Infants were randomized to receive a modified BlalockTaussig shunt versus a right ventricle-pulmonary artery shunt as part of their Norwood procedure and were followed for 14 months with serial assessment. The study was approved by the local institutional review boards, and informed consent for study participation was obtained from the parents or legal guardians. Data collection included patient demographics and baseline characteristics, operative variables, hospitalization course, clinical outcomes, and echocardiographic assessment of right ventricular ejection fraction (RVEF). All echocardiograms were reviewed centrally by an independent observer at the echocardiography core laboratory.
14,15
Genotyping
Buccal swab epithelial cells were collected at enrollment or during Norwood hospitalization with CytoSoft cytology brushes (Medical Packaging Corporation, Camarillo, Calif) after informed consent was obtained. Methods have been reported previously. 16 Genomic DNA was extracted with a PureGene kit (Gentra Systems, Inc, Minneapolis, Minn) according to the manufacturer's protocol. Samples were retrieved from the PHN Biorepository for genotyping. Participants in the SVR Trial who did not Adrenergic receptor single-nucleotide polymorphisms (SNPs) were selected on the basis of previous association studies, functional effects, and population allele frequencies. 13, 17, 18 Genotyping (Sequenom SNP) was performed for 4 SNPs in 3 adrenergic receptor (ADR) genes: a A/G missense variant at position 231 in ADRB1 resulting in a serine to glycine substitution (rs1801252), a C/G missense variant at position 1165 in ADRB1 resulting in a glycine to arginine substitution (rs1801253), a C/G missense variant at position 5318 in ADRB2 resulting in a glutamine to glutamic acid substitution (rs1042714), and a C/T 3 0 untranslated region variant at position 2790 in ADR2A (rs553668). Patients carrying a single copy of the variant allele or SNP (also known as minor allele) at the genetic locus were defined as having a heterozygous genotype, those with 2 copies of the variant allele as having a homozygous genotype, and those without a variant allele, ie, carrying only the normal allele (also known as major allele) were defined as having a wild-type genotype.
Because variants in the renin-angiotensin-aldosterone signaling (RAAS) pathway genes have been associated previously with adverse ventricular remodeling in infants with single-ventricle lesions, genotyping also was performed for 4 SNPs and 1 insertion-deletion variant in 5 RAAS genes. The following were considered RAAS-upregulation genotypes based on our previous work: AGT_CC, ACE_DD, AGTR1_CC, CYP11B2_CC, and CMA1_AA. The CYP11B2 and CMA1 variants were genotyped with Sequenom SNP genotyping and the AGTR1, AGT, and the ACE insertion/deletion polymorphisms were genotyped with TaqMan primers and probes. For samples and SNPs that did not yield a valid result by Sequenom or TaqMan analysis, PCR amplification followed by Sanger sequencing was performed. The detailed genotyping methods, primers, and probes for the Sequenom SNP analysis, the Taqman analysis and for the PCR amplification or Sanger sequencing are listed in Appendix E1 and Table E1 .
Statistical Analysis
Allele and genotype frequencies were determined to calculate HardyWeinberg equilibrium. All demographic and clinical data were expressed as frequencies, mean with standard deviations, or medians with interquartile ranges. The primary outcome was a composite of any serious adverse event (SAE) during a 14-month follow-up after the Norwood procedure and included death, transplant, need for postoperative extracorporeal membrane oxygenation, postoperative cardiopulmonary resuscitation, acute shunt failure, unplanned reoperations, or necrotizing enterocolitis. 19, 20 Secondary outcomes included frequency of post-Norwood complications up to hospital discharge from stage 2 surgery and RVEF during 14 months follow-up. Complications were defined as adverse events using the common terminology criteria for adverse events version 3.0 developed by the National Cancer Institute, National Institutes of Health, but that did not meet criteria for SAEs. 20 Because post-Norwood hospital and intensive care unit length of stay were highly correlated with each other and with Norwood complication rate when analyzed using bootstrap Spearman rank correlation (data not shown), these outcomes were not analyzed separately.
ADR genotype associations were analyzed by comparing outcomes in homozygous or heterozygous SNP carriers versus wild-types using a dominant model. Freedom from the primary outcome was described with the Kaplan-Meier method with stratification by genotype. The log-rank test was used to assess between-stratum differences. Cox proportional hazard models adjusted for covariates of interest were used to test the association of the genotypes with the primary outcome. The proportional hazards assumption was verified using cumulative Martingale process plots. Associations were quantified by hazard ratios and reported along with their 95% confidence intervals. P values were calculated based on Wald statistics. Poisson regression adjusted for overdispersion and for exposure time (number of days of hospitalization for Norwood procedure) was used to model the association of risk genotype with frequency of post-Norwood complications and results were presented as incidence rate ratios with 95% confidence intervals. A mixed model was used to assess for association of genotype with RVEF during 14 months' follow-up. All analyses were adjusted for sex, race, birth weight, gestational age, presence of aortic atresia or obstructed pulmonary venous return, presence of a genetic syndrome, age at Norwood procedure, total Norwood cardiopulmonary bypass time, deep hypothermic circulatory arrest time, type of shunt, and presence of a RAAS-upregulation genotype. 21 The covariates selected were not found to exhibit significant collinearity. In regression models, when patients had missing data on the presence of identifiable syndromes, it was assumed that identifiable syndromes were not present. Observations with missing data in other variables were excluded from the models and this represented a very small percentage of the total cohort. All statistical analyses were performed with SAS v9.4 (SAS Institute, Cary, NC).
RESULTS
Of 555 patients in the SVR trial, 436 provided DNA and 351 had complete genotype data (ie, genotyping results for all 9 SNPs) and were included in the analysis (Figure 1 ). ADR genotype frequencies are shown in Table 1 . All genotypes were in Hardy-Weinberg equilibrium. Patient clinical characteristics and outcomes in the group with complete versus incomplete genotypes are shown in Table 2 . The only significant difference was a greater incidence of death in the completely genotyped cohort compared with the incompletely genotyped cohort. Incomplete genotyping was the result of technical issues such as low quality or quantity of DNA. The results hereby focus on the 351 subjects with complete genotype data.
We evaluated the association of ADR genotypes with the primary outcome of composite SAEs. Sixty-four percent of patients had the ADRA2A_2790CC genotype (wild-type). Kaplan-Meier analysis showed that patients with the CC (Table 2 ). Complications by systems are shown in Table 5 . The list of complications included for this trial have been published previously. 20 Cardiac complications included arrhythmias, pericardial effusion, hypotension or hypertension, RV dysfunction, valvar insufficiency, and other. We evaluated the association of ADR genotypes with the rate of complications after the Norwood procedure using Poisson regression. All regression models were adjusted for demographic, clinical, and surgical risk factors as well as for RAAS genotypes and the Poisson regression was adjusted for exposure time. There were no significant differences in incidence rates of Norwood complications by genotype (Figure 3) . ADR genotypes were not associated with significant difference in RV function during 14-month follow-up (data not shown) as assessed by mixed-effects models adjusted for clinical and surgical factors.
DISCUSSION
In an era of precision medicine, there is a growing recognition of the importance of identifying not just clinical predictors but also genetic predictors of outcomes that can be used to individualize care and improve the safety and efficacy of medical and surgical interventions based on the unique genome and phenome of a patient. Previous studies have identified genetic variants that increase susceptibility to neurodevelopmental outcomes and adverse ventricular remodeling in single-ventricle patients undergoing staged palliation as well as in patients with other types of congenital heart disease undergoing surgical repair. 16, [21] [22] [23] [24] In this study, we evaluated the association of genetic variants that increase ADR signaling with post-Norwood outcomes in infants with HLHS. Using genetic material collected during the trial, we demonstrated that the ADR genotype is an important predictor of outcomes of stage 1 palliation in infants with HLHS with lower SAE-free survival in patients harboring ADR risk genotypes. Although further study is required, these findings may have implications for individualizing perioperative management in this cohort based on genotype.
We evaluated 2 SNPs in the ADRB1 gene and one in the ADRB2 gene. The ADRB1_389GG genotype has been associated previously with pediatric and adult heart failure, and the ADRB1_231AA genotype is known to be associated with lower basal adenylate cyclase activity but increased sensitivity of the b1 receptor to norepinephrine with enhanced sympathetic blood pressure response. 17, 25 Neither ADRB1 genotype nor the ADRB2 genotype were associated with postoperative complications or SAEs in our study. 10 The ADR2A receptor is important in regulating vascular tone as well as metabolic responses like insulin release from pancreatic cells and adipocyte metabolism in humans. Genetic variations lead to alterations in G-protein coupling and in agonist-promoted receptor phosphorylation and desensitization thereby modulating response to catecholamines. 12 The ADRA2A_2790CC genotype (wild-type) has been reported to cause reduced feedback inhibition of norepinephrine and failure to inhibit sympathetic tone. 26 Although we did not measure sympathetic tone, we found that patients with the CC genotype had lower freedom from SAEs during 14-month follow-up compared with CT/TT genotypes. One explanation for this finding is that a milieu of high-circulating catecholamines in patients with the CC genotype may have resulted in increased vasomotor tone and an adverse effect on systemic output and organ perfusion, thereby increasing the risk of post-Norwood SAEs. The event-free survival curves diverged relatively sharply after the early postoperative period, at around 15 days (Figure 1 ). This suggests that although early events were more likely secondary to surgical complications that were similar in both genotype groups, later events were more likely influenced by genetic differences in adrenergic system-mediated adaptation to the Norwood circulation as well as recovery from complications. Overall, our findings suggest that genotypes associated with increased adrenergic neurohormonal activation and responsiveness may have a detrimental effect in the post-Norwood circulation. A limitation of our study is that only a small number of candidate SNPs were analyzed. The DNA in the trial was acquired via buccal swabs, which required polymerase chain reaction amplification and did not yield sufficient quantity or quality of DNA for a more unsupervised approach using whole-exome sequencing. Nonetheless, the SNPs were selected carefully based on previous associations with outcomes in other pediatric cardiac studies. Also, RV myocardial samples and detailed hemodynamic data were not collected during the Norwood procedure for the trial precluding assessment of tissue adrenergic receptor expression, and of potential influence of the genotypes on metabolic and hemodynamic function. In addition, we were unable to evaluate the pharmacogenetic influences of the ADR genotypes with b-blocker response because less than 5% patients were receiving b-blocker therapy during follow-up. Also, the sample size of this study was reduced because of insufficient DNA or incomplete genotyping in the trial cohort. Nonetheless, the baseline characteristics of the genotyped and non-genotyped cohorts were similar excluding a survival bias in our study cohort.
In summary, ADR genotypes that enhance catecholamine levels and/or sensitivity increase the risk of SAEs in patients who survive beyond the first 2 weeks after the Norwood procedure. Further studies are needed to delineate the biological and hemodynamic effects of these genotypes and to validate these findings in additional cohorts. Pharmacologic modification of adrenergic receptors has been shown to positively influence outcome in other heart failure cohorts. [27] [28] [29] Although there is no evidence to support empiric b-blocker use in patients with HLHS, studies are needed to determine whether preoperative identification of these genetic subtypes can be used to target b-blockers and/or other forms of more aggressive systemic vasodilation post-Norwood to the subset with these risk genotypes.
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APPENDIX E1. SUPPLEMENTAL GENOTYPING METHODS
Sequenom SNP typing for the ADR SNPs was performed by the University of Michigan DNA Sequencing Core. Assays were designed with standard Sequenom software (Sequenom, San Diego, Calif; both online Assay Design Suite tools and desktop Assay Design 4.0) and performed using a Sequenom MassARRAY Compact instrument, according to manufacturer's standard protocols. Results were processed to generate single-nucleotide polymorphism (SNP) calls automatically, using Sequenom TyperAnalyzer software, and then manually reviewed by the operator to validate the allele calls. Automatic SNP calls that were of concern, based on questionable spectra, were removed. Sequenombased SNP typing was successful in ADRB2 (rs1042714) in 372 of 384 subjects, in ADRA2 (rs553668) in 362 of 384 subjects, in ADRB1 (rs1801253) in 338 of 384 subjects, and in ADRB1 (rs1801252) in 320 of 384 subjects.
Genotyping for the ACE I/D polymorphism was performed using a TaqMan assay as previously described.
E1
Reactions were carried out in 96-well microtiter plates in a CFX96 Real Time System (Bio-Rad Laboratories, Hercules, Calif). The assay volume of 22 mL consisted of 11 mL of 2x Absolute QPCR ROX mix (ABgene), 150 nmol/L each primer (ACE111, ACE112, ACE113), 75 nmol/L Fam-ACE100 (Deletion allele specific probe) and 150 nmol/L VIC-ACE100 (Insertion allele-specific probe), and 1 mL of DNA ($50 ng). After denaturation for 10 minutes at 95 C, amplification involved 45 cycles of denaturation at 95 C for 15 seconds, and primer annealing and extension at 57 C for 1 minute. Genotyping for the AGTR1 and AGT SNPs also were performed using the CFX96 Real Time System (Bio-Rad). The assay volume of 5 mL consisted of 2.5 mL of 2x TaqMan Universal PCR reaction mix no AmpErase UNG (Thermo Fisher Scientific, Waltham, Mass), 0.125 mL of SNP-specific 40x primer/probe reaction mix (Thermo Fisher Scientific), and 0.5 mL of DNA ($25 ng). Amplification involved 40 cycles of denaturation at 95 C for 15 seconds and primer annealing and extension at 60 C for 1 minute. Subject samples were run along with controls representing the possible genotypes for each assay as well as a no template control. Postamplification analysis of the genotypes at each codon was performed with the allelic discrimination analysis module of the CFX Manager Software V. 3.1 (Bio-Rad).
For those samples and SNPs that did not yield a valid result by Sequenom or TaqMan analysis, polymerase chain reaction (PCR) amplification followed by Sanger sequencing was performed. PCR primers were selected with the LaserGene Primer Select Program (DNASTAR Inc, Madison, Wis). A 12-mL PCR was set up for each DNA sample to be tested. Each 12-mL PCR contained 10 to 40 ng of genomic patient or control DNA (1 mL), 1 mL of 1.5 pmol forward primer, 1 mL of 1.5 pmol reverse primer, 3 mL of DNase/RNase free water, and 6 mL of HotStarTaq polymerase mixture (QIAGEN, Inc, Valencia, Calif). PCR DNA amplification was performed on a thermal cycler (Bio-Rad My-Cycler; Bio-Rad Life Sciences) as previously described. E2 To summarize in brief, a touchdown PCR protocol was used as follows: initial denaturation at 94 C for 15 minutes, followed by 24 cycles with an annealing temperature decreasing 0.7 C per cycle, starting at 72 C for 30 seconds; denaturation at 94 C for 30 seconds, and extension at 72 C for 1 minute. An additional 32 cycles were added: 94 C for 30 seconds, 55 C for 30 seconds, 72 C for 1 minute, with a final extension of 72 mC for 10 minutes. Sanger sequencing of the amplicons were performed by the University of Michigan DNA Sequencing Core facility with an Applied Biosystems DNA Sequencer (Model 3730 XL). Each chromatogram was visually inspected with Applied Biosystems Sequence Scanner (v1.0) software to determine genotypes. Primers and probes for the Sequenom SNP analysis, the Taqman analysis, and for the PCR amplication/Sanger sequencing are listed in Table E1 . Combining the Sequenom-based and the PCR-based results, SNP typing was successful in ADRB2 (rs1042714) in 384 of 384 subjects, in ADRA2 (rs553668) in 384 of 384 subjects, in ADRB1 (rs1801253) in 383 of 384 subjects, and in ADRB1 (rs1801252) in 383 of 384 subjects. 
